BOSTON, April 12, 2012 /PRNewswire/ -- Perceptive
Informatics, a leading eClinical solutions provider and a
subsidiary of PAREXEL International Corporation (NASDAQ: PRXL),
today introduced the new Site Inventory Management Module of its
ClinPhone® Randomization and Trial Supply Management
(RTSM) solution. The RTSM technologies from Perceptive Informatics
offer validated randomization methods, automated inventory control,
dispensing and titration management, emergency code break
capabilities, and supply reporting. This new web-based module is
designed to improve the efficiency of clinical trial management by
tracking the movement of supplies at clinical sites in real-time
and streamlining workflow for site personnel.
The introduction of the Site Inventory Management Module
reinforces a commitment by PAREXEL and Perceptive Informatics to
help sponsors meet critical trial milestones and avoid delays due
to lack of available study drug caused by late or incomplete
arrival of clinical supplies at sites. Through advanced approaches
and systems, the Company is focused on real-time confirmation of
study supplies and allowing site investigators to more quickly
begin using study drugs according to trial protocols. PAREXEL
Clinical Logistics Services are supported by enabling technology
solutions, including the ClinPhone RTSM solution.
The Site Inventory Management Module provides clinical site
personnel with real-time study drug tracking information and
efficient tools to take actions based on this information. Advanced
features include visibility of drug expiration information, data
filtering, simple selection and confirmation of actions, and
multi-lingual capability.
"With greater clinical trial complexity, sites require the
necessary tools for seamless access to data in order to make
better, faster decisions," said Nick
Richards, Vice President, Product Management, Perceptive
Informatics. "With the introduction of this web-based module, we
are enabling site teams to work in a more dynamic and interactive
way, and bring more efficiency to trial supply chain
processes."
The ClinPhone RTSM solution has been used in over 3,000 studies
involving more than 289,000 sites and 1.7 million patients. The
RTSM technologies provide sophisticated reporting to monitor trial
management performance, trending and forecasting information, and
in-depth data analysis. Clinical trials worldwide can be supported
in multiple languages through the solution, which provides secure
access, a detailed audit trail, transaction logging, and compliance
with FDA 21 CFR Part 11.
For more information about the RTSM solution from Perceptive
Informatics visit: http://www.perceptive.com/clinphone-rtsm/.
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider
and subsidiary of PAREXEL, is focused on helping customers to
accelerate the product development process through innovation.
Perceptive enables customers to maximize the benefits of clinical
trial technologies by providing flexible software-as-a-service
(SaaS) applications and leading technology services. The Perceptive
Informatics eClinical Suite is built on extensive medical and
clinical expertise, as well as a deep understanding of the
regulatory environment. The suite includes Randomization and Trial
Supply Management (RTSM) technologies, Medical Imaging, Clinical
Trial Management Systems (CTMS), Electronic Data Capture (EDC), and
Electronic Patient-Reported Outcomes (ePRO). The Perceptive
Informatics eClinical Suite blurs the boundaries among systems that
traditionally have been used in isolation, resulting in simplified
workflow, improved efficiency and enhanced productivity. For more
information about the integrated solutions in the Perceptive
Informatics eClinical Suite visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
knowledge-based contract research, consulting, and medical
communications services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. Perceptive
Informatics, Inc., a subsidiary of PAREXEL, provides advanced
technology solutions, including medical imaging, to facilitate the
clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71
locations throughout 52 countries around the world, and has
approximately 11,300 employees. For more information about PAREXEL
International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ significantly from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings,
including the anticipated additional restructuring charges of
approximately $2.0 million in the
third quarter of Fiscal Year 2012; the loss, modification, or delay
of contracts which would, among other things, adversely impact the
Company's recognition of revenue included in backlog; the Company's
dependence on certain industries and clients; the Company's ability
to win new business, manage growth and costs, and attract and
retain employees; the Company's ability to complete additional
acquisitions and to integrate newly acquired businesses or enter
into new lines of business; the impact on the Company's business of
government regulation of the drug, medical device and
biotechnology industry; consolidation within the pharmaceutical
industry and competition within the biopharmaceutical services
industry; the potential for significant liability to clients and
third parties; the potential adverse impact of health care reform;
and the effects of exchange rate fluctuations and other
international economic, political, and other risks.
Such factors and others are discussed more fully in the section
entitled "Risk Factors" of the Company's Quarterly Report on Form
10-Q for the quarter ended December 31,
2011 as filed with the SEC on February 9, 2012, which "Risk Factors" discussion
is incorporated by reference in this press release. The
Company specifically disclaims any obligation to update these
forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International
Corporation, ClinPhone is a registered trademark of ClinPhone
Limited, and Perceptive Informatics is a registered trademark of
Perceptive Informatics, Inc. All other names or marks may be
registered trademarks or trademarks of PAREXEL International
Corporation, Perceptive Informatics, Inc. or their respective
owners and are hereby acknowledged.
Contacts:
|
|
Georgina
Cattaway, Director of Marketing and Public Relations
|
Kim
Leadley/Gene Carozza
|
PAREXEL
International
|
PAN
Communications
|
Tel: +44
1895 614530
|
Tel: +
617-502-4300
|
Email:
Georgina.Cattaway@PAREXEL.com
|
Email:
PAREXEL@pancomm.com
|
SOURCE PAREXEL International Corporation